Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769958 | 0.88 | NEK2 (0.51) | MAPTKDM4ELMNACYP46A1ALDH1A1 | |
| SCHEMBL2080144 | 0.88 | CYP3A4 (0.51) | CYP3A4MAPTKDM4EABL1LMNA | |
| SCHEMBL1940737 | 0.85 | CYP3A4 (0.67) | CYP3A4MAPTKDM4EABL1LMNA | |
| SCHEMBL15770491 | 0.85 | KDM4E (0.60) | MAPTKDM4ELMNAGAACYP46A1 | |
| SCHEMBL1938489 | 0.84 | CYP3A4 (0.50) | CYP3A4MAPTKDM4EABL1LMNA | |
| SCHEMBL3436398 | 0.84 | CYP3A4 (0.50) | CYP3A4KDM4EABL1LMNAGAA | |
| SCHEMBL15770497 | 0.83 | CYP46A1 (0.64) | MAPTCYP46A1 | |
| SCHEMBL1939980 | 0.83 | CYP3A4 (0.49) | CYP3A4MAPTKDM4EABL1LMNA | |
| SCHEMBL15783900 | 0.81 | MAPT (0.52) | MAPTKDM4EGAACYP46A1ALDH1A1 | |
| SCHEMBL31468011 | 0.81 | ATR (0.53) | CYP3A4MAPTKDM4ELMNACYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CYP3A4 1991/4885MAPT 1330/4885KDM4E 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.